Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients: A Prospective Observational Multicenter Postmarketing Study.
[Neuropathology of multiple sclerosis].
[Pathogenesis of neuromyelitis optica].
Symptomatic Sinus Bradycardia After a Treatment Course Of High-dose Oral Prednisone.
Neuromyelitis optica and pregnancy.
Early onset (childhood) monogenic neuropathies.
Inflammation subverts hippocampal synaptic plasticity in experimental multiple sclerosis.
Autoimmune neurological disorders associated with group-A beta-hemolytic streptococcal infection.
Structural equation modeling of factors contributing to quality of life in Japanese patients with multiple sclerosis.
Platelets and autoimmunity.
CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.
Do Bugs Control Our Fate? The Influence of the Microbiome on Autoimmunity.
Multiple sclerosis and co-morbid autoimmune disease: the final nail in the coffin?
PET imaging in multiple sclerosis.
To be 17 again--anti-interleukin-17 treatment for psoriasis.
Enhanced remyelination following lysolecithin-induced demyelination in mice under treatment with fingolimod (FTY720).
DQB1*06:02-Associated Pathogenic Anti-Myelin Autoimmunity in Multiple Sclerosis-Like Disease: Potential Function of DQB1*06:02 as a Disease-Predisposing Allele.
No evidence for CCVSI in relapsing-remitting multiple sclerosis patients with moderate disability.
Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes.
Multiple sclerosis: Effect of smoking on antibody response to IFN-β treatment.
Multiple sclerosis severity score in a cohort of Moroccan patients.
Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
Second generation S1P pathway modulators: Research strategies and clinical developments.
Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy.
Selection and optimization of therapy for progressive type multiple sclerosis.

Pages